We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

MEDIX BIOCHEMICA AB

Develops, produces and markets monoclonal antibodies, antibody services and recombinant antigens for IVD industry, as... read more Featured Products: More products

Download Mobile App





Medix Biochemica Celebrates Launch of New Molecular Diagnostic Reagents Division at MEDICA 2021

By LabMedica International staff writers
Posted on 15 Nov 2021

Medix Biochemica (Espoo, Finland) celebrated the launch of its new molecular diagnostic reagents division, MedixMDx at this year's MEDICA, the world's largest annual medical technology trade fair, which took place from 15-18 November in Düsseldorf, Germany. More...

Medix, including Lee Biosolutions, EastCoast Bio and Diaclone, is a leading global supplier of critical raw materials used for in vitro diagnostics (IVD). Medix recently acquired Diaclone, a prominent provider of monoclonal antibodies in the areas of inflammation, oncology, and immunology. At MEDICA 2021, Medix showcased its wide portfolio of monoclonal antibodies, antigens for immunoassay materials, molecular diagnostics reagents, enzymes for clinical chemistry controls, and biochemicals and biological.

Medix highlighted its range of quality reagents offered through MedixMDx in combination with a host of custom services to provide IVD kit manufacturers, labs and research institutions with the tailored support they need from proof-of-concept right through to release for sale. In addition to highlighting its wide range of high-quality reagents and master mixes designed to shorten development timelines and work with various assay technologies, Medix also threw light on its technical support provided to clients as they develop their assays as well as contract manufacturing services.

Medix highlighted its broad range of platform-agnostic reagents, including enzymes, nucleic acid extraction products, buffers and as well as consumables. The company showcased its range of enzymes, ready mixes, controls, clinical specimens and general reagents in the areas of PCR/qPCR, isothermal nucleic acid amplification technologies (iNAAT), Next generation Sequencing (NGS).

Related Links:
Medix Biochemica 


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.